ΔF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 4, 2010, Pages 268-278

  Rowe, S M ^a,b,c,f   Pyle, L C ^e,f   Jurkevante, A ^c   Varga, K ^c   Collawn, J ^c,f   Sloane, P A ^a   Woodworth, B ^d,f   Mazur, M ^f   Fulton, J ^a   Fan, L ^b,f   Li, Y ^b,f   Fortenberry, J ^a,f   Sorscher, E J ^a,c,f   Clancy, J P ^b,f  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Kentucky   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

CFTR; Cystic fibrosis; Ion transport

Indexed keywords

COMPLEMENTARY DNA; CYCLIC AMP; FORSKOLIN; GENISTEIN; PAPAVERINE; PHOSPHODIESTERASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; PHOSPHATASE; PHOSPHODIESTERASE INHIBITOR;

AIRWAY; ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; BRONCHUS; CELL TYPE; CHLORIDE TRANSPORT; CONDUCTANCE; CONTROLLED STUDY; CYSTIC FIBROSIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW TEMPERATURE; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; FISCHER 344 RAT; ION TRANSPORT; METABOLISM; TEMPERATURE;

ANIMALS; CELLS, CULTURED; CHLORIDES; CYCLIC AMP; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; FORSKOLIN; GENISTEIN; HUMANS; ION TRANSPORT; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC MONOESTER HYDROLASES; RATS; RATS, INBRED F344; TEMPERATURE;

EID: 77953122968     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.02.001     Document Type: Article

References (67)

1. Anderson M.P., Gregory R.J., Thompson S., Souza D.W., Paul S., Mulligan R.C., et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253 (1991) 202-205
2. Anderson M.P., Rich D.P., Gregory R.J., Smith A.E., and Welsh M.J. Generation of cAMP-activated chloride currents by expression of CFTR. Science 251 (1991) 679-682
3. Rowe S.M., Miller S., and Sorscher E.J. Cystic fibrosis. N Engl J Med 352 (2005) 1992-2001
4. Stutts M.J., Canessa C.M., Olsen J.C., Hamrick M., Cohn J.A., Rossier B.C., et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 269 (1995) 847-850
5. Ward C.L., and Kopito R.R. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 269 (1994) 25710-25718
6. Ward C.L., Omura S., and Kopito R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83 (1995) 121-127
7. Younger J.M., Chen L., Ren H.Y., Rosser M.F., Turnbull E.L., Fan C.Y., et al. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell 126 (2006) 571-582
8. Wang X., Venable J., LaPointe P., Hutt D.M., Koulov A.V., Coppinger J., et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127 (2006) 803-815
9. Du K., Sharma M., and Lukacs G.L. The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12 (2005) 17-25
10. Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W., White G.A., et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63 (1990) 827-834
11. Denning G.M., Anderson M.P., Amara J.F., Marshall J., Smith A.E., and Welsh M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358 (1992) 761-764
12. Bear C.E., Li C.H., Kartner N., Bridges R.J., Jensen T.J., Ramjeesingh M., et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68 (1992) 809-818
13. Egan M.E., Glockner-Pagel J., Ambrose C., Cahill P.A., Pappoe L., Balamuth N., et al. Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 8 (2002) 485-492
14. Brown C.R., Hong-Brown L.Q., Biwersi J., Verkman A.S., and Welch W.J. Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1 (1996) 117-125
15. Guay-Broder C., Jacobson K.A., Barnoy S., Cabantchik Z.I., Guggino W.B., Zeitlin P.L., et al. A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator ΔF508 mutation. Biochemistry 34 (1995) 9079-9087
16. Rubenstein R.C., Egan M.E., and Zeitlin P.L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR. J Clin Invest 100 (1997) 2457-2465
17. Sato S., Ward C.L., Krouse M.E., Wine J.J., and Kopito R.R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271 (1996) 635-638
18. Bebok Z., Venglarik C.J., Panczel Z., Jilling T., Kirk K.L., and Sorscher E.J. Activation of ΔF508 CFTR in an epithelial monolayer. Am J Physiol 275 (1998) C599-607
19. Pedemonte N., Lukacs G.L., Du K., Caci E., Zegarra-Moran O., Galietta L.J., et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115 (2005) 2564-2571
20. Rubenstein R.C. Novel, mechanism-based therapies for cystic fibrosis. Curr Opin Pediatr 17 (2005) 385-392
21. Yang H., Shelat A.A., Guy R.K., Gopinath V.S., Ma T., Du K., et al. Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating. J Biol Chem 278 (2003) 35079-35085
22. Van Goor F., Straley K.S., Cao D., Gonzalez J., Hadida S., Hazlewood A., et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290 (2006) L1117-1130
23. Hwang T.C., Wang F., Yang I.C., and Reenstra W.W. Genistein potentiates wild-type and ΔF508-CFTR channel activity. Am J Physiol 273 (1997) C988-998
24. Wang F., Zeltwanger S., Yang I.C., Nairn A.C., and Hwang T.C. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 111 (1998) 477-490
25. Al-Nakkash L., and Hwang T.C. Activation of wild-type and ΔF508-CFTR by phosphodiesterase inhibitors through cAMP-dependent and -independent mechanisms. Pflugers Arch 437 (1999) 553-561
26. Swiatecka-Urban A., Brown A., Moreau-Marquis S., Renuka J., Coutermarsh B., Barnaby R., et al. The short apical membrane half-life of rescued {delta}f508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {delta}f508-CFTR in polarized human airway epithelial cells. J Biol Chem 280 (2005) 36762-36772
27. Li C., Ramjeesingh M., Reyes E., Jensen T., Chang X., Rommens J.M., et al. The cystic fibrosis mutation (delta F508) does not influence the chloride channel activity of CFTR. Nat Genet 3 (1993) 311-316
28. Ostedgaard L.S., Rogers C.S., Dong Q., Randak C.O., Vermeer D.W., Rokhlina T., et al. Processing and function of CFTR-ΔF508 are species-dependent. Proc Natl Acad Sci U S A 104 (2007) 15370-15375
29. Liu X., Luo M., Zhang L., Ding W., Yan Z., and Engelhardt J.F. Bioelectric properties of chloride channels in human, pig, ferret, and mouse airway epithelia. Am J Respir Cell Mol Biol 36 (2007) 313-323
30. Varga K., Jurkuvenaite A., Wakefield J., Hong J.S., Guimbellot J.S., Venglarik C.J., et al. Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines. J Biol Chem 279 (2004) 22578-22584
31. Wu X., Wakefield J.K., Liu H., Xiao H., Kralovics R., Prchal J.T., et al. Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2 (2000) 47-55
32. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Cao D., Neuberger T., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, Vx-770. Proc Natl Acad Sci U S A (2009)
33. Rowe S.M., Li Y., Rab A., Kirk K.L., Wang W., Bebok Z., et al. Evidence for retained function following recombinant expression of W1282X CFTR in vitro. Pediatr Pulmonol Suppl 40 (2005) 208
34. - airway epithelial monolayers. J Physiol 569 (2005) 601-615
35. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
36. Varga K., Goldstein R.F., Jurkuvenaite A., Chen L., Matalon S., Sorscher E.J., et al. Enhanced cell-surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 410 (2008) 555-564
37. Jurkuvenaite A., Varga K., Nowotarski K., Kirk K.L., Sorscher E.J., Li Y., et al. Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis. J Biol Chem 281 (2006) 3329-3334
38. Peter K., Varga K., Bebok Z., McNicholas-Bevensee C.M., Schwiebert L., Sorscher E.J., et al. Ablation of internalization signals in the carboxyl-terminal tail of the cystic fibrosis transmembrane conductance regulator enhances cell surface expression. J Biol Chem 277 (2002) 49952-49957
39. Clancy J.P., Hong J.S., Bebok Z., King S.A., Demolombe S., Bedwell D.M., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain 1 (NBD-1) and CFTR truncated within NBD-1 target to the epithelial plasma membrane and increase anion permeability. Biochemistry 37 (1998) 15222-15230
40. - secretion in Calu-3 cells. Am J Respir Cell Mol Biol 29 (2003) 410-418
41. Rowe S.M., Varga K., Rab A., Bebok Z., Byram K., Li Y., et al. Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol (2007)
42. - secretion in human subjects by adenosine. Am J Respir Cell Mol Biol 31 (2004) 140-146
43. - conductance. Am J Physiol 266 (1994) L502-512
44. Springsteel M.F., Galietta L.J., Ma T., By K., Berger G.O., Yang H., et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 11 (2003) 4113-4120
45. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101 (2004) 296-301
46. Kelley T.J., Al-Nakkash L., Cotton C.U., and Drumm M.L. Activation of endogenous ΔF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest 98 (1996) 513-520
47. Schultz B.D., Frizzell R.A., and Bridges R.J. Rescue of dysfunctional ΔF508-CFTR chloride channel activity by IBMX. J Membr Biol 170 (1999) 51-66
48. Penmatsa H., Zhang W., Yarlagadda S., Li C., Conoley V.G., Yue J., Bahouth S.W., et al. Compartmentalized cAMP at the plasma membrane clusters PDE3A and CFTR into microdomains. Mol Biol Cell. 21 6 (2010) 1097-1110
49. Pedemonte N., Tomati V., Sondo E., and Galietta L.J. Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol (2010) [Epub]
50. Knowles M.R., Paradiso A.M., and Boucher R.C. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6 (1995) 445-455
51. Standaert T.A., Boitano L., Emerson J., Milgram L.J., Konstan M.W., Hunter J., et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 37 (2004) 385-392
52. Rowe S.M., Accurso F., and Clancy J.P. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 4 (2007) 387-398
53. Rubenstein R.C., and Zeitlin P.L. A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in ΔF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157 (1998) 484-490
54. McCarty N.A., Standaert T.A., Teresi M., Tuthill C., Launspach J., Kelley T.J., et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol 33 (2002) 90-98
55. Pyle L.C., Fulton J.C., Sloane P.A., Backer K., Mazur M., Prasain J., et al. Activation of CFTR by the flavonoid quercetin: potential use as a biomarker of ΔF508 CFTR rescue. Am J Respir Cell Mol Biol (2009)
56. Skach W.R. CFTR: new members join the fold. Cell 127 (2006) 673-675
57. Wang F., Zeltwanger S., Hu S., and Hwang T.C. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 524 Pt 3 (2000) 637-648
58. Wang W., Bernard K., Li G., and Kirk K.L. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 282 (2007) 4533-4544
59. Pedemonte N., Sondo E., and Galietta L.J. Evaluation of potentiators and correctors for the functional rescue of δF508 CFTR protein. Pediatr Pulmonol Suppl 42 (2007) A268
60. Bronsveld I., Mekus F., Bijman J., Ballmann M., de Jonge H.R., Laabs U., et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of ΔF508 homozygous twins and siblings. J Clin Invest 108 (2001) 1705-1715
61. Derichs N., Mekus F., Bronsveld I., Bijman J., Veeze H.J., von der Hardt H., et al. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in f508del homozygous cystic fibrosis patients. Pediatr Res 55 (2004) 69-75
62. Naren A.P., Nelson D.J., Xie W., Jovov B., Pevsner J., Bennett M.K., et al. Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms. Nature 390 (1997) 302-305
63. Naren A.P., Di A., Cormet-Boyaka E., Boyaka P.N., McGhee J.R., Zhou W., et al. Syntaxin 1a is expressed in airway epithelial cells, where it modulates CFTR Cl(-) currents. J Clin Invest 105 (2000) 377-386
64. + exchanger 3 regulatory factor 1 (NHERF-1)- but not NHERF-2-deficient mice. J Biol Chem 282 (2007) 37575-37584
65. Treharne K.J., Xu Z., Chen J.H., Best O.G., Cassidy D.M., Gruenert D.C., et al. Inhibition of protein kinase CK2 closes the CFTR Cl channel, but has no effect on the cystic fibrosis mutant ΔF508-CFTR. Cell Physiol Biochem 24 (2009) 347-360
66. Kongsuphol P., Cassidy D., Hieke B., Treharne K.J., Schreiber R., Mehta A., et al. Mechanistic insight into control of CFTR by AMPK. J Biol Chem 284 (2009) 5645-5653
67. Loo T.W., Bartlett M.C., Wang Y., and Clarke D.M. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J 395 (2006) 537-542